Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Argus Health
Chinese Patent Office
Farmers Insurance
Covington
UBS
Queensland Health
US Army
Fish and Richardson

Generated: May 20, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,030,447

« Back to Dashboard

Summary for Patent: 5,030,447
Title: Pharmaceutical compositions having good stability
Abstract:A pharmaceutical compositions is provided which has excellent stability, when dispersed in water has a pH of at least about 9, and includes a medicament which is sensitive to a low pH environment such as pravastatin, one or more fillers such as lactose and/or microcrystalline cellulose, one or more binders, such as mirocrystalline cellulose (dry binder) or polyvinylpyrrolidone (wet binder), one or more disintegrating agents such as croscarmellose sodium, one or more lubricants such as magnesium stearate and one or more basifying agents such as magnesium oxide.
Inventor(s): Joshi; Yatindra M. (Piscataway, NJ), Chiesa; Pierina (South Orange, NJ), Jain; Nemichand B. (Monmouth Junction, NJ)
Assignee: E. R. Squibb & Sons, Inc. (Princeton, NJ)
Application Number:07/176,127
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,030,447
Patent Claims: 1. A pharmaceutical composition in the form of a tablet which has enhanced stability comprising medicament which is sensitive to a low pH environment and is pravastatin, one of more fillers, one or more binders, one or more disintegrants, one of more lubricants and one or more basifying agents to impart a desired pH of at least 9 to an aqueous dispersion of said composition.

2. The pharmaceutical composition as defined in claim 1 wherein said medicament is present in an amount within the range of from about 1 to about 60% by weight of the composition.

3. The pharmaceutical composition as defined in claim 1 wherein the basifying agent is present in an amount within the range of from about 1 to about 75% by weight of the composition.

4. The pharmaceutical composition as defined in claim 1 wherein the basifying agent is an alkali metal hydroxide, an alkaline earth metal hydroxide or ammonium hydroxide.

5. The pharmaceutical composition as defined in claim 5 wherein the basifying agent is MgO, Mg(OH).sub.2, Ca(OH).sub.2, NaOH, KOH, LiOH, NH.sub.4 OH, Al(OH).sub.3 or magaldrate.

6. The pharmaceutical composition as defined in claim 1 wherein the filler is present in an amount within the range of from about 5 to about 90% by weight.

7. The pharmaceutical composition as defined in claim 6 wherein the filler is lactose, sugar, corn starch, modified corn starch, mannitol, sorbitol, wood cellulose, microcrystalline cellulose, calcium carbonate or mixtures thereof.

8. The pharmaceutical composition as defined in claim 1 wherein the binder is present in an amount within the range of from about 5 to about 35% by weight.

9. The pharmaceutical composition as defined in claim 8 wherein the binder is microcrystalline cellulose, polyvinylpyrrolidone, lactose, corn starch, modified corn starch, sugars, gum acacia, carnauba wax, paraffin, spermaceti, polyethylenes or microcrystalline wax.

10. The pharmaceutical composition as defined in claim 1 wherein the disintegrant is present in an amount within the range of from about 0.5 to about 10% by weight.

11. The pharmaceutical composition as defined in claim 10 wherein the disintegrant is croscarmellose sodium, crospovidone, sodium starch glycolate, corn starch or microcrystalline cellulose.

12. The pharmaceutical composition as defined in claim 1 having the following formulation:

from about 3 to about 50% by weight pravastatin,

from about 2 to about 70% by weight magnesium oxide, to impart a pH of at least about 9.5,

from about 1 to about 85% by weight lactose,

from about 10 to about 30% by weight microcrystalline cellulose or polyvinylpyrrolidone,

from about 2 to about 8% by weight of croscarmellose sodium; and

from about 0.5 to about 2% by weight magnesium stearate.

13. The pharmaceutical composition as defined in claim 1 having a pH in water of at about 10.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Daiichi Sankyo
Healthtrust
Medtronic
Moodys
Chubb
US Army
Citi
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.